Aisling Capital Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 10
- Investments
- 223
- Portfolio
- 18
- Exits
- 150
Aisling Capital General Information
Description
Founded in 2000, Aisling Capital is a venture capital firm based in New York, New York. The firm prefers to invest in early-stage companies. The firm seeks to make investments in the technology, biopharma, consumer, diagnostics, medical device, service, and life-sciences sectors.
Contact Information
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Primary Office
- 888 Seventh Avenue
- 12th Floor
- New York, NY 10106
- United States
+1 (212) 000-0000
Aisling Capital Investments & Acquisitions (223)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Antios Therapeutics | 12-Apr-2021 | Early Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
| 00000000 000000000 | 12-Apr-2021 | 00000 00000 | 00000 | Biotechnology | Stealth | |
| 00000 0000 0000000 | 21-Mar-2021 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue/Not Profitable | 000000 000000 00 |
| 00000 | 16-Mar-2021 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue/Not Profitable | 000000 0000000 |
| 000000 000000 | 23-Dec-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 1 | 0000 000000 00 |
| 000000000 00000000 | 12-Nov-2020 | 00000 00000 | 0000 | Drug Discovery | Clinical Trials - Phase 2 | |
| 00000000 000 | 15-Oct-2020 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
| 0000000 0000000000 | 30-Sep-2020 | 00000 00000 | 00000 | Biotechnology | Clinical Trials - Phase 3 | |
| Monte Rosa Therapeutics | 15-Sep-2020 | Early Stage VC | 0000 | Drug Discovery | Generating Revenue/Not Profitable | 000000 000000 00 |
| Spruce Biosciences | 07-Aug-2020 | Early Stage VC | 0000 | Drug Discovery | Clinical Trials - Phase 2 |
Aisling Capital Exits (150)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Talaris Therapeutics | 07-May-2021 | IPO | 00000 |
| 000000 000000 | 16-Apr-2021 | 000 | 00000 |
| 00000 | 09-Apr-2021 | 000 | 000.00 |
| 0000000 | 24-Feb-2021 | 000000000000000000 | |
| 00000000 000 | 10-Feb-2021 | 0000000 000000 | 00000 |
| 0000000 0000000000 | 13-Oct-2020 | 000000000000000000 | 00.00 |
| 000000 00000000000 | 09-Oct-2020 | 000 | 0000 |
| 0000000 0000000000 | 19-Aug-2020 | 000 | 00000 |
| Poseida Therapeutics | 10-Jul-2020 | IPO | 00000 |
| EarLens | 06-Apr-2020 | Secondary Transaction - Private |
Aisling Capital Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is available in the PitchBook Platform. To explore Aisling Capital‘s full profile, request access.
Request a free trialAisling Capital Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialAisling Capital Team (34)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Robert Wenzel | Chief Financial Officer & Chief Compliance Officer, Legal | New York, NY | |||
| Andrew Schiff MD | Managing Partner | 00 | 0 | 0 | New York, NY |
| Steven Elms | Managing Partner | 00 | 0 | 0 | New York, NY |
| Eric Aguiar MD | Partner | 00 | 0 | 0 | New York, NY |
| Stacey Seltzer | Partner | 0 | 0 | 0 | New York, NY |
Aisling Capital Co-Investors (139)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Cormorant Asset Management | 8 | 0 | 0 |
|
|
| Boxer Capital | 0 | 0 | 0 |
|
|
| Rock Springs Capital | 0 | 0 | 0 |
|
|
| Vivo Capital | 0 | 0 | 0 |
|
|
| HBM Healthcare Investments | 0 | 0 | 0 |
|
|